[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-nodule-solitary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-nodule-solitary":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,52,85,113,137,162,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644877","intraoperative-longitude-latitude-depth-localization-versus-preoperative-ct-guided-percutaneous-lung-puncture-localization-for-08-2-cm-peripheral-pulmonary-nodules-100644877",false,"NCT07675889","Intraoperative Longitude-Latitude-Depth Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for 0.8-2 cm Peripheral Pulmonary Nodules","Intraoperative Longitude-Latitude-Depth Three-Dimensional Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for the Treatment of 0.8-2 cm Peripheral Pulmonary Nodules: A Multicenter, Randomized, Open-Label, Non-Inferiority Clinical Trial","Inclusion Criteria:\n\n* Clinically diagnosed pulmonary nodule by non-contrast chest CT.\n* Age 18 to 80 years.\n* Expected survival time of at least 12 months.\n* Single peripheral pulmonary nodule with a diameter between 0.8 cm and 2 cm.\n* Chest CT characteristics meeting both of the following criteria:\n\n  1. Solid component proportion ≤50%.\n  2. Located subpleurally or in the outer one-third of the lung parenchyma.\n* Willing to undergo VATS-assisted sublobar resection.\n* No contraindications to pulmonary localization procedures or surgery.\n* Able to understand the study and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* Use of other localization methods or other surgical procedures.\n* Concurrent participation in another clinical study.\n* Pregnancy.\n* Unwillingness or inability to cooperate with participation in this study for any reason.","ALL","18 Years","80 Years",{"count":20,"type":21},274,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether intraoperative longitude-latitude-depth three-dimensional localization (LLD localization) is non-inferior to preoperative CT-guided percutaneous lung puncture localization for identifying 0.8-2 cm peripheral pulmonary nodules in adults undergoing video-assisted thoracoscopic surgery (VATS)-assisted sublobar resection. It will also evaluate the safety and perioperative effectiveness of the two localization methods. The main questions it aims to answer are:\n\n1. Is the localization accuracy rate of LLD localization non-inferior to that of CT-guided percutaneous lung puncture localization?\n2. Does LLD localization improve perioperative outcomes, including localization time, postoperative recovery, pain, quality of life, and perioperative complication rates?\n\nResearchers will compare LLD localization with CT-guided percutaneous lung puncture localization to determine whether LLD localization provides comparable localization accuracy while reducing procedure-related complications and improving perioperative outcomes.\n\nParticipants will:\n\n1. Be randomly assigned in a 1:1 ratio to either the LLD localization group or the CT-guided percutaneous lung puncture localization group.\n2. Undergo pulmonary nodule localization using the assigned localization method.\n3. Receive VATS-assisted sublobar resection following localization.\n4. Be assessed for localization accuracy, perioperative complications, localization time, postoperative chest drainage tube removal time, oxygenation index, postoperative hospital stay, pain scores, and quality-of-life outcomes.\n5. Complete follow-up assessments at 1, 3, and 6 months after surgery.",[27,28,29],"Pulmonary Nodule, Solitary","Peripheral Pulmonary Nodules","Pulmonary Nodules",[31,32,33,34,35,36,37,38],"Peripheral Pulmonary Nodule","Pulmonary Nodule Localization","Longitude-Latitude-Depth Localization","CT-Guided Percutaneous Localization","Video-Assisted Thoracoscopic Surgery","Sublobar Resection","Randomized Controlled Trial","Non-Inferiority Trial","NOT_YET_RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-30","ACTUAL",{"date":45,"type":21},"2026-07-01",{"date":47,"type":21},"2028-07-01",{"name":49,"class":50},"Qilu Hospital of Shandong University","OTHER",4,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100513701","assessment-of-a-radiomics-based-computer-aided-diagnosis-tool-for-pulmonary-nodules-100513701","NCT05968898","Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES","Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Cancer Risk Stratification of Pulmonary Nodules","ARCADES","Inclusion Criteria:\n\n1. Male or female, aged 35-89 years\n2. Scheduled to be evaluated at a UPHS PN clinic\n3. Newly discovered solid or part-solid indeterminate PN 8-30mm in maximal diameter on CT imaging within 60 days of index clinic visit\n4. Chest CT imaging meeting the technical requirements for compatibility with Optellum Virtual Nodule Clinic software\n\nExclusion Criteria:\n\n1. Chest CT imaging with discrete mediastinal or hilar lymphadenopathy by CT size criteria (\\>10mm in maximal short-axis diameter on axial CT images)\n2. PNs with popcorn calcification (consistent with benign etiology)\n3. Pure ground-glass subsolid PNs (may be associated with lower risk of clinically significant malignancy)\n4. PN previously seen on CT imaging \\>60 days prior to most recent CT\n5. More than one indeterminate PN 8-30mm in maximal diameter\n6. History of lung cancer\n7. History of active cancer within the previous 5 years\n8. Presence of a thoracic implant that impedes PN visualization","35 Years","89 Years",{"count":63,"type":21},300,[24],"This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.",[67,27],"Lung Cancer",[69,70,71,72,73],"clinical effectiveness","clinical utility","artificial intelligence","medical decision-making","risk stratification","RECRUITING","2026-06-01",{"date":77,"type":43},"2026-06-02",{"date":79,"type":43},"2024-01-09",{"date":81,"type":21},"2030-07-31",{"name":83,"class":50},"Abramson Cancer Center at Penn Medicine",3,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100617759","smoking-cessation-before-bronchoscopy-or-ct-guided-puncture-100617759","NCT07322796","Smoking Cessation Before Bronchoscopy or CT-guided Puncture","Smoking Cessation Before Intervention in Patients With Pulmonary Nodules Requiring Further Diagnosis","Inclusion Criteria:\n\n* The patient is an active smoker by the time of the initial presentation in our pneumological outpatient clinic for the clarification of a suspicious nodule\n\nExclusion Criteria:\n\n* Current or past medically relevant illness or treatment that could affect the evaluability of the study.\n* Expected lack of willingness to actively participate in study-related measures.",{"count":93,"type":21},25,"3 Months","OBSERVATIONAL","Nicotine is the most common preventable cause of death and is responsible for over seven million deaths worldwide. If current trends continue, tobacco will kill more than eight million people worldwide every year by 2030. Smoking tobacco products is the most important risk factor for the development of lung cancer. Passive smoking is also a major cause of lung cancer. Since July 2024, smokers and former smokers have been able to receive a low-radiation CT scan under certain conditions to detect lung cancer at an early stage. It is therefore to be expected that the number of diagnoses of pulmonary lesions or nodules will increase in the near future. The risk of developing and dying from tobacco-related diseases is reduced once nicotine cessation begins. Screening all patients for tobacco use, e-cigarette use, and providing behavioral counseling and pharmacotherapy to quit smoking are among the most valuable preventive services we can offer in healthcare.\n\nNicotine dependence can be estimated using the so-called Fagerström test. An additional evaluation of nicotine behavior can be carried out by testing cotinine in urine, a method that is used, for example, in the listing for lung transplantation. Cotinine is a degradation product of nicotine that can be detected in the urine of smokers and passive smokers. Cotinine levels in urine depend on the frequency and quantity of nicotine consumption. The half-life of cotinine is 16 to 22 hours, which means that half of the cotinine is excreted from the body after this time. Another marker that can be used as a measure of tobacco consumption is carboxyhaemoglobin (COHb). This is hemoglobin with carbon monoxide at the binding site for oxygen. The reference range for carboxyhaemoglobin is 0.4 - 1.6 %. In smokers, values of 3-10 % are still considered normal.\n\nIn our department, the smoking status of patients is assessed upon first contact. Support options for smoking cessation are offered and, upon request, initiated. Previous studies have shown that smoking is a risk factor for complications after thoracic surgical procedures and that patients who underwent thoracic surgery quit smoking almost twice as often compared to patients who did not undergo surgery. However, to the best of our knowledge, there is currently no study regarding smoking cessation before intervention in patients with nodules needing clarification (bronchoscopy or CT-guided puncture).\n\nTherefore, the aim of the study is to support and monitor smoking cessation before intervention in patients with nodules needing further diagnosis (bronchoscopy or CT-guided puncture).",[27,98],"Smoking Behaviors",[100,101,102],"smoking","smoking cessation","pulmonary nodules","2026-01-26",{"date":105,"type":43},"2026-01-28",{"date":107,"type":43},"2026-01-01",{"date":109,"type":21},"2027-12-31",{"name":111,"class":50},"RWTH Aachen University",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100469205","dolce-determining-the-impact-of-optellums-lung-cancer-prediction-solution-100469205","NCT05389774","DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution","DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction (LCP) Artificial Intelligence Solution on Service Utilisation, Health Economics and Patient Outcomes","DOLCE","Inclusion Criteria:\n\nPatients are eligible for the study if all of the following apply:\n\n* Are aged 35 years or above\n* Have baseline CT study with at least one incidentally detected solid or part-solid (must have a solid component \\>=80%) pulmonary nodule that:\n\n  * is not fully calcified\n  * Is 5-30mm inclusive in maximum axial diameter for the whole lesion measured using manual electronic callipers\n* Have baseline CT study that includes at least one series that meets all of the following (training for this will be provided):\n\n  * Is of a type that meets VNC instructions for use\n  * Comprises at least one full-inspiration breath-hold scans without a high degree of contrast media and does not exhibit quality issues (e.g., motion artefacts)\n\nExclusion Criteria:\n\nPatients will be excluded from the study if any of the following apply:\n\n* Have received a diagnosis for cancer in the last 5 years\n* Have thoracic implants that impact the image appearance of the nodule\n* Have more than five reported pulmonary nodules of any size or type excluding fully calcified nodules (this criterion is used as a proxy due to the risk of being an infection or metastasis)\n* Have one or more additional nodules where any of the following applies:\n\n  * Are already undergoing follow-up according to pulmonary nodule management standard care\n  * Pure ground glass opacity (GGO) of \\>=5mm in maximum axial diameter for the whole lesion measured using manual electronic callipers\n  * \\>30mm in maximum axial diameter for the whole lesion measured using manual electronic callipers",{"count":122,"type":21},2000,"This study is a multi-centre prospective observational cohort study recruiting patients with 5-30mm solid and part-solid pulmonary nodules that have been detected on CT chest scans performed as part of routine practice. The aim is to determine whether physician decision making with the AI-based LCP tool, generates clinical and health-economic benefits over the current standard of care of these patients.",[125,27,126,67],"AI (Artificial Intelligence)","Pulmonary Nodule, Multiple","2025-04-04",{"date":129,"type":43},"2025-04-08",{"date":131,"type":43},"2023-03-23",{"date":133,"type":21},"2025-08",{"name":135,"class":50},"Nottingham University Hospitals NHS Trust",10,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":161},"100548871","clinical-utility-of-management-of-patients-with-pulmonary-nodules-using-the-percepta-nasal-swab-classifier-100548871","NCT06426628","Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier","Clinical Utility of Management of Patients With CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier","NIGHTINGALE","Inclusion Criteria:\n\n* Able to tolerate nasal epithelial specimen collection\n* Signed written Informed Consent obtained\n* Subject clinical history available for review by sponsor and regulatory agencies\n* New nodule identified on imaging \\\u003C 90 days prior to nasal sample collection\n* CT report available for index nodule\n* 29 - 85 years of age\n* Current or former smoker (\\>100 cigarettes in a lifetime)\n* Pulmonary nodule ≤30 mm detected by CT\n\nExclusion Criteria:\n\n* Active cancer (other than non-melanoma skin cancer)\n* Prior primary lung cancer (prior non-lung cancer acceptable)\n* Prior participation in this study (i.e., subjects may not be enrolled more than once)\n* Current active treatment with an investigational device or drug\n* Patient enrolled or planned to be enrolled in another clinical trial that may influence management of the patient's nodule\n* Concurrent or planned use of tools or tests for assigning lung nodule risk of malignancy other than clinically validated risk calculators","29 Years","85 Years",{"count":148,"type":21},2400,"The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule.\n\nThe main questions it aims to answer are:\n\n* Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign?\n* Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is cancer?\n\nParticipants will be randomly assigned to either a group where the test result is provided to the physician (test arm) or to a group where the test result is not provided (control arm). Researchers will compare management of participants in the two groups.",[27,67],"2024-11-12",{"date":153,"type":43},"2024-11-13",{"date":155,"type":43},"2022-07-18",{"date":157,"type":21},"2027-03-31",{"name":159,"class":160},"Veracyte, Inc.","INDUSTRY",23,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":4},"100475924","comparative-study-on-the-efficacy-and-safety-of-microwave-ablation-and-lobectomy-in-the-treatment-of-ground-glass-nodules-located-in-the-pulmonary-hilar-region-100475924","NCT05477251","Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodules Located in the Pulmonary Hilar Region","Inclusion Criteria:\n\n1. The age ranged from 18 to 75 years old, male or female;\n2. GGO lesions in the hilar region were diagnosed by imaging examination (CT \u002F PET-CT). During the follow-up of 6-12 months, the lesions increased by more than 2mm, the solid components increased, or there were obvious solid components, or the GGOs were judged to be highly malignant by imaging.\n3. The size of GGO lesions was 8mm-3cm, and the number of nodules was ≤ 3.\n4. There was no lymph node metastasis, intrapulmonary metastasis or distant organ metastasis;\n5. After multidisciplinary evaluation, the patients were feasible for lobectomy and CT guided microwave treatment;\n6. No bleeding tendency, normal coagulation function or coagulation dysfunction can be corrected after treatment;\n7. Patients and \u002For family members agreed to join the clinical trial and signed informed consent.\n\nExclusion Criteria:\n\n1. The general condition of the patient is very poor, ECOG physical fitness score \\> 2, unable to tolerate lobectomy and MWA treatment, or has relevant contraindications;\n2. The lesions had received other treatments before; patients with regional lymph node metastasis or distant metastasis or with pleural fluid and ascites;\n3. Patients with poor compliance;\n4. Severe heart, lung, kidney, brain and other important organ diseases;\n5. The researcher believes that it is not suitable for inclusion","75 Years",{"count":170,"type":21},100,[24],"GGO is a characteristic focus of early lung cancer. Due to the abundant peripheral blood vessels and bronchial tissues around the GGO lesions located in pulmonary hilar, only lobectomy could be used for the surgical treat of hilar GGO lesions which will make the significantly decline of the pulmonary function after surgery and affect the quality of life to a great extent. Our previous study has reported a new blunt-tip MWA electrode (MTC-3CA-II3, Vison Medical Inc.) for the treatment of GGO lesions. The blunt-tip MWA electrode could improve the safety of GGO ablation, significantly reduce the occurrence of bleeding and hemoptysis, which made it possible to ablate GGO in the hilar region safely. In this study, the blunt-tip MWA electrode was used in the treatment of patients with hilar GGO lesions, and the efficacy and safety of microwave ablation and lobectomy in the treatment of ground glass nodules located in the pulmonary hilar region were evaluated and compared.",[126,27],"2022-08-09",{"date":176,"type":43},"2022-08-11",{"date":178,"type":21},"2022-10-01",{"date":180,"type":21},"2026-12-31",{"name":182,"class":50},"RenJi Hospital",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":95,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100366296","pulmonary-nodule-cohort-100366296","NCT04049422","Pulmonary Nodule Cohort","liquidNodule","Inclusion Criteria:\n\n* age \\>= 18\n* pulmonary nodule(s) on chest CT, which satisfy at least one of the following two criteria,\n\n  * 4A or above in Lung-RADS v1.1\n  * lung cancer risk \\>= 5% in Brock model\n\nExclusion Criteria:\n\n* already proven lung cancer",{"count":191,"type":21},1000,"5 Years","The aim of this study is to identify the clinical features of pulmonary nodules and establish a cohort to identify biomarkers for lung cancer.",[27,67],"2019-08-06",{"date":197,"type":43},"2019-08-08",{"date":195,"type":21},{"date":200,"type":21},"2029-07-31",{"name":202,"class":50},"Seoul National University Hospital"]